Fig. 1 · Structure
Documents & Downloads
ICI 185282
TXA₂ Receptor Antagonist
ICI 185282 is a selective thromboxane A2 (TXA₂) receptor antagonist that exhibits potent, orally active inhibition. It effectively reduces U-46619-induced platelet aggregation in a dose-dependent manner in guinea pig models. Additionally, ICI 185282 demonstrates efficacy in preventing bronchospasm triggered by various inflammatory mediators such as PGD2, PGF2α, arachidonic acid, LTD4, and PAF in vivo. This compound is valuable for research in bronchial asthma and related respiratory conditions.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 106393-80-0 |
| Applications | TXA₂ Receptor Antagonist |
| Formula | C18H21F3O5 |
| Molecular Weight | 374.35 |
| SMILES | O=C(O)CCC/C=C\C[C@@H]1[C@H](C2=CC=CC=C2O)O[C@H](C(F)(F)F)OC1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.